Unknown

Dataset Information

0

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.


ABSTRACT: Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of potential use in patients with breast cancer. Unfortunately, in clinical studies, gefitinib is often ineffective indicating that resistance to EGFR inhibitors may be a common occurrence in cancer of the breast. EGFR has been shown to be overexpressed in breast cancer, and in particular remains hyperphosphorylated in cell lines such as MDA-MB-468 that are resistant to EGFR inhibitors. Here, we investigate the cause of this sustained phosphorylation and the molecular basis for the ineffectiveness of gefitinib. We show that reactive oxygen species (ROS), known to damage cellular macromolecules and to modulate signaling cascades in a variety of human diseases including cancers, appear to play a critical role in mediating EGFR TKI-resistance. Furthermore, elimination of these ROS through use of a cell-penetrating catalase derivative sensitizes the cells to gefitinib. These results suggest a new approach for the treatment of TKI-resistant breast cancer patients specifically, the targeting of ROS and attendant downstream oxidative stress and their effects on signaling cascades.

SUBMITTER: Giordano CR 

PROVIDER: S-EPMC3858180 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

Giordano Courtney R CR   Mueller Kelly L KL   Terlecky Laura J LJ   Krentz Kendra A KA   Bollig-Fischer Aliccia A   Terlecky Stanley R SR   Boerner Julie L JL  

Experimental cell research 20120608 16


Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of potential use in patients with breast cancer. Unfortunately, in clinical studies, gefitinib is often ineffective indicating that resistance to EGFR inhibitors may be a common occurrence in cancer of the breast. EGFR has been shown to be overexpressed in breast cancer, and in particular remains hyperphosphorylated in cell lines such as MDA-MB-468 that are resistant to EGFR inhibitors. Here, we investigate t  ...[more]

Similar Datasets

| S-EPMC10506422 | biostudies-literature
| S-EPMC6151264 | biostudies-literature
| S-EPMC9179491 | biostudies-literature
| S-EPMC3681494 | biostudies-literature
| S-EPMC6126699 | biostudies-literature
| S-EPMC3589701 | biostudies-literature
| S-EPMC6406301 | biostudies-literature
2010-02-09 | GSE18964 | GEO
| PRJNA352077 | ENA
2016-11-02 | GSE89411 | GEO